Valuation dashboard for Evolus, Inc. (EOLS) with P/E N/A, P/B -17.05, EV/EBITDA -62.16 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc.
Analysis Summary
Evolus, Inc. reported revenue of $297.2M in the most recent fiscal year, growing at a 5-year CAGR of 39.4%.
Trailing-twelve-month margins: gross margin 66.2%, operating margin -7.3%, net margin -10.8%.
At the current price of $7.99, EOLS has negative trailing earnings (P/E not meaningful) and an ROE of 123.11%. Market capitalisation stands at $526M.
Balance sheet quality for EOLS: current ratio of 1.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -17.05 |
| EV / EBITDA | -62.16 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $8.58 |
| vs Current Price | +7.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EOLS | Evolus, Inc. | $526M | 123.1% | ||
| TAK | Takeda Pharmaceutical Company Limited | $59.3B | 50.64 | 1.20 | 2.4% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.9B | 58.46 | 5.53 | 9.2% |
| HLN | Haleon plc | $40.6B | 18.74 | 1.85 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.9B | 20.08 | 2.08 | 10.1% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price
| Price | $7.99 |
| Market Cap | $526M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 123.11% |
| Return on Invested Capital | -15.27% |
| Return on Assets | -13.84% |
| Gross Margin | 66.25% |
| Operating Margin | -7.33% |
| Net Margin | -10.85% |
Related companies: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of EOLS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks